Literature DB >> 28425121

Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.

Rachel I Anderson1, Howard C Becker1,2,3.   

Abstract

Evidence has demonstrated that dynorphin (DYN) and the kappa opioid receptor (KOR) system contribute to various psychiatric disorders, including anxiety, depression, and addiction. More recently, this endogenous opioid system has received increased attention as a potential therapeutic target for treating alcohol use disorders. In this review, we provide an overview and synthesis of preclinical studies examining the influence of alcohol (ethanol [EtOH]) exposure on DYN/KOR expression and function, as well as studies examining the effects of DYN/KOR manipulation on EtOH's rewarding and aversive properties. We then describe work that has characterized effects of KOR activation and blockade on EtOH self-administration and EtOH dependence/withdrawal-related behaviors. Finally, we address how the DYN/KOR system may contribute to stress-EtOH interactions. Despite an apparent role for the DYN/KOR system in motivational effects of EtOH, support comes from relatively few studies. Nevertheless, review of this literature reveals several common themes: (i) rodent strains genetically predisposed to consume more EtOH generally appear to have reduced DYN/KOR tone in brain reward circuitry; (ii) acute and chronic EtOH exposure typically up-regulate the DYN/KOR system; (iii) KOR antagonists reduce behavioral indices of negative affect associated with stress and chronic EtOH exposure/withdrawal; and (iv) KOR antagonists are effective in reducing EtOH consumption, but are often more efficacious under conditions that engender high levels of consumption, such as dependence or stress exposure. These results support the contention that the DYN/KOR system plays a significant role in contributing to dependence- and stress-induced elevation in EtOH consumption. Overall, more comprehensive analyses (on both behavioral and mechanistic levels) are needed to provide additional insight into how the DYN/KOR system is engaged and adapts to influence the motivation effects of EtOH. This information will be critical for the development of new pharmacological agents targeting KORs as promising novel therapeutics for alcohol use disorders and comorbid affective disorders.
Copyright © 2017 by the Research Society on Alcoholism.

Entities:  

Keywords:  Dynorphin; Ethanol Consumption; Ethanol Dependence; Kappa Opioid Receptor

Mesh:

Substances:

Year:  2017        PMID: 28425121      PMCID: PMC5522623          DOI: 10.1111/acer.13406

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  138 in total

1.  Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.

Authors:  Yan Zhou; Rachel Saylor Crowley; Konrad Ben; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2017-03-02       Impact factor: 3.252

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  Involvement of mu- and delta-opioid receptors in the ethanol-associated place preference in rats exposed to foot shock stress.

Authors:  S Matsuzawa; T Suzuki; M Misawa; H Nagase
Journal:  Brain Res       Date:  1998-08-24       Impact factor: 3.252

4.  Prefrontal Cortical Kappa Opioid Receptors Attenuate Responses to Amygdala Inputs.

Authors:  Hugo A Tejeda; Ashley N Hanks; Liam Scott; Carlos Mejias-Aponte; Zoë A Hughes; Patricio O'Donnell
Journal:  Neuropsychopharmacology       Date:  2015-05-14       Impact factor: 7.853

5.  Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles.

Authors:  A L Svingos; C Chavkin; E E Colago; V M Pickel
Journal:  Synapse       Date:  2001-12-01       Impact factor: 2.562

6.  Alteration of kappa-opioid receptor system expression in distinct brain regions of a genetic model of enhanced ethanol withdrawal severity.

Authors:  Amy S Beadles-Bohling; Kristine M Wiren
Journal:  Brain Res       Date:  2005-06-07       Impact factor: 3.252

7.  Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens.

Authors:  A Rosin; S Lindholm; J Franck; J Georgieva
Journal:  Neurosci Lett       Date:  1999-11-05       Impact factor: 3.046

8.  Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.

Authors:  Lei Zhou; Edward L Stahl; Kimberly M Lovell; Kevin J Frankowski; Thomas E Prisinzano; Jeffrey Aubé; Laura M Bohn
Journal:  Neuropharmacology       Date:  2015-07-06       Impact factor: 5.250

9.  Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.

Authors:  Albert J Arias; Stephen Armeli; Joel Gelernter; Jonathan Covault; Antero Kallio; Sakari Karhuvaara; Tiina Koivisto; Rauno Mäkelä; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

Review 10.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

View more
  32 in total

1.  mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking in mice.

Authors:  Yan Zhou; Yupu Liang; Mary Jeanne Kreek
Journal:  Pharmacol Biochem Behav       Date:  2020-05-26       Impact factor: 3.533

Review 2.  A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity.

Authors:  Marc A Schuckit
Journal:  Alcohol Clin Exp Res       Date:  2018-04-05       Impact factor: 3.455

3.  Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2019-08-27       Impact factor: 3.252

4.  Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.

Authors:  Shawn M Flynn; Phillip M Epperly; April T Davenport; Gerta Cami-Kobeci; Stephen M Husbands; Mei-Chuan Ko; Paul W Czoty
Journal:  Neuropsychopharmacology       Date:  2019-04-10       Impact factor: 7.853

Review 5.  The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?

Authors:  Matthew B Pomrenze; Tracy L Fetterly; Danny G Winder; Robert O Messing
Journal:  Alcohol Clin Exp Res       Date:  2017-10-25       Impact factor: 3.455

6.  Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol.

Authors:  Rachel I Anderson; David E Moorman; Howard C Becker
Journal:  Handb Exp Pharmacol       Date:  2018

7.  Dynorphin-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice.

Authors:  Rachel I Anderson; Marcelo F Lopez; William C Griffin; Harold L Haun; Daniel W Bloodgood; Dipanwita Pati; Kristen M Boyt; Thomas L Kash; Howard C Becker
Journal:  Neuropsychopharmacology       Date:  2018-12-11       Impact factor: 7.853

Review 8.  Dynorphins in Development and Disease: Implications for Cardiovascular Disease.

Authors:  Cody Cissom; Jason J Paris; Zia Shariat-Madar
Journal:  Curr Mol Med       Date:  2020       Impact factor: 2.222

9.  Kappa opioid receptors in the bed nucleus of the stria terminalis regulate binge-like alcohol consumption in male and female mice.

Authors:  Harold L Haun; William C Griffin; Marcelo F Lopez; Howard C Becker
Journal:  Neuropharmacology       Date:  2020-02-02       Impact factor: 5.250

10.  Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice.

Authors:  Yan Zhou; Rachel Crowley; Thomas Prisinzano; Mary Jeanne Kreek
Journal:  Neurosci Lett       Date:  2018-02-26       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.